key: cord-0921178-6qvcv9yx
authors: Olea, B.; Albert, E.; Torres, I.; Gozalvo-Rovira, R.; Carbonell, E.; Ferreres, J.; Poujois, S.; Costa, R.; Colomina, J.; Rodriguez, J.; Blasco, M. L.; Navarro, D.
title: SARS-CoV-2 RNA load in the lower respiratory tract, viral RNAemia and N-antigenemia in critically ill adult COVID-19 patients: relationship with biomarkers of disease severity
date: 2021-04-16
journal: nan
DOI: 10.1101/2021.04.16.21255601
sha: c47a41a66cd4d5a93e1cda02a1808120d32607f3
doc_id: 921178
cord_uid: 6qvcv9yx

Background: Little is known about the comparative kinetics of SARS-CoV-RNA load in the lower respiratory tract and in blood compartment in patients admitted to the intensive care unit, and how these relate to biomarkers of COVID-19 severity. Methods: Seventy-three consecutive critically ill COVID-19 patients (median age, 65 years) were recruited. Serial lower respiratory tract (n=165) and plasma (n=340) specimens were collected. RT-PCR and lateral flow immunochromatography assay were used for SARS-CoV-2 RNA quantitation and N protein detection in plasma, respectively. Serum levels of inflammatory and tissue-damage biomarkers in paired specimens were analyzed. Results: SARS-CoV-RNA was detected in the lower respiratory tract of most patients (92%). Viral RNAemia and N-antigenemia were documented in 35.6% and 40.1% of patients, respectively. Viral RNAemia and N-antigenemia cleared at a faster rate than SARS-CoV-2 RNA in tracheal aspirates (TA). SARS-CoV-2 RNA load was higher (P<0.001) in TA than in plasma, and correlated significantly (Rho, 0.41; P<0.001). A modest correlation was found between SARS-CoV-2 RNA load in TA and plasma and levels of ferritin and lactose dehydrogenase (Rho[≤]0.3; P[≤]0.008) in paired serum specimens. Neither the dynamics of SARS-CoV-2 RNA load in TA and plasma, nor N-antigenemia detection rate differed between surviving and deceased patients. Yet, a trend towards a higher mortality was seen in patients with viral RNAemia (OR; 2.82; 95% CI, 0.94-8.47; P=0.06).

Severe COVID-19 is a multisystem disease involving the lower respiratory tract (LRT) Abbott RealTime SARS-CoV-2 assay, a dual target reverse transcription polymerase 117 chain reaction (RT-PCR) assay amplifying the RdRp and N-genes, on the m2000rt 118 platform, following the manufacturer's instructions. The analytical sensitivity of the 119 RT-PCR assay in TA and plasma specimens was assessed by spiking (in quintuplicate) 120 10-10 4 copies/ml of the AMPLIRUN® TOTAL SARS-CoV-2 RNA Control (Vircell 121 SA, Granada, Spain) into RT-PCR negative TA or plasma samples. The limit of 122 detection (LOD) was found to be approximately 100 copies/ml (95%) for both matrices 123

(not shown), in agreement with previous estimates using NP [30, 31] . SARS-CoV-2 124 viral loads are given in copies/ml throughout the study, as estimated using the 125 abovementioned reference material. All specimens from a given patient were analysed 126 in the same run in singlets. 127

The CLINITEST Ⓡ Rapid COVID-19 Antigen Test (Siemens, Healthineers, Erlangen, 129 Germany), a lateral flow immunochromatography (LFIC) device licensed for detection 130 of SARS-CoV-2 nucleocapsid protein NP or nasal swabs, was used on plasma 131 specimens. The limit of detection (LOD) of the assay in plasma was determined by 132 spiking a pre-pandemic plasma pool testing negative by RT-PCR with 10, 25, 50, 100 133 and 150 pg/ml of a recombinant N protein (MT-25C19NC, Certest Biotec S.L., 134

Zaragoza, Spain). The LOD was found to be at least 50 pg/ml ( Supplementary Fig. 1) . 135

Depleting experiments using a rabbit anti-N protein antibody (40143-R019; 136

SinoBiological) confirmed the true nature of SARS-CoV-2 N detected in a number of 137 discordant plasma specimens (testing negative by RT-PCR), as described in 138 supplementary methods and shown in Supplementary Fig. 2 . 139

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted April 16, 2021. ; https://doi.org/10.1101/2021.04.16.21255601 doi: medRxiv preprint Clinical laboratory tests included serum levels of ferritin, D-Dimer (D-D), C reactive 141 protein (CRP), interleukin-6 (IL-6), lactose dehydrogenase (LDH) and absolute 142 lymphocyte counts. 143

Frequency comparisons for categorical variables were carried out using Fisher's exact 145 test. Differences between medians were compared using the Mann-Whitney U test. 146

Spearman's rank test was used for analysis of correlation between continuous variables. 147

Two-sided exact P values were reported. A P value <0.05 was considered statistically 148 significant. The level of agreement between qualitative results provided by paired 149 virological assays was assessed using Kappa-Cohen statistics. Logistic regression 150 analyses were performed to assess risk factors for all-cause mortality. Parameters 151

yielding P values <0.1 in univariate analyses were introduced in multivariate models. 152

The analyses were performed using SPSS version 20.0 (SPSS, Chicago, IL, USA). 153

Patients were admitted to ICU at a median of 9 days (range, 2-25) after onset of 156 symptoms. All patients presented with pneumonia and imaging findings compatible 157 with COVID-19 on chest-x ray or CT-scan, and most eventually needed mechanical 158 ventilation (87.7%). Median time of ICU stay was 18 days (range, 2-67). A total of 16 159 and 27 patients were under remdesivir and tocilizumab treatment, respectively, at ICU 160 admission. Corticosteroids were given to 70 patients. A total of 29 patients died, at a 161 median of 22 days (range, 7-66) after ICU admission. 162

Kinetics of SARS-CoV-2 RNA load in the lower respiratory tract 163 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) Of the 64 patients undergoing mechanical ventilation, 61 had one or more TA collected 164 (total number, 165; median of 2 specimens/patient; range, 1-11). The remaining three 165 patients were not sampled. SARS-CoV-2 RNA was detected in 109 TA from 56 patients 166 (91.8%). The remaining five patients tested negative for SARS-CoV-2 RNA in TA but 167 had one or more positive NP collected prior to mechanical ventilation. 168 SARS-CoV-2 RNA load in TA ranged between 3.03 and 10.6 log 10 copies/ml (median, 169 6.5 log 10 copies/ml). The dynamics of SARS-CoV-2 RNA load over time in TA is 170 shown in Fig. 1A . Viral load remained relatively stable across the first two weeks from 171 symptoms onset and began to decrease afterwards. No patient tested positive for SARS-172

CoV-2 RNA in TA beyond day 42. 173

Neither remdesivir nor tocilizumab administration appeared to have a major impact on 174 the dynamics of SARS-CoV-2 load in TA (Fig. 2, Supplementary Table 1) . 175

A total of 340 plasma specimens from 73 patients (median, 4 samples/patient; range, 1-177 16) were available for analyses. SARS-CoV-2 RNAemia could be detected in 37 plasma 178 specimens from 26 patients (35.6%). Median time to first detection of viral RNA in 179 plasma was 10 days after symptoms onset (range, 3-32 days). The range of SARS-CoV-180 2 RNA loads measured in plasma was 1.69 to 5.27 log 10 copies/ml. Median SARS-CoV-181 2 RNA load was significantly lower in plasma (3.03 log 10 copies/ml) than in paired TA 182 (Fig. 3A) . A moderate yet significant correlation was found between SARS-CoV-2 183 RNA levels in TA and in paired plasma specimens (Fig. 3B ). The dynamics of viral 184

RNAemia are shown in Fig. 1B . SARS-CoV-2 RNAemia cleared at a faster rate than 185 viral load in TA. In fact, viral RNAemia was not detected beyond day 32 after onset of 186 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted April 16, 2021. ; https://doi.org/10.1101/2021.04.16.21255601 doi: medRxiv preprint symptoms. A similar conclusion was drawn taking only paired TA and plasma 187 specimens into consideration for the analyses (Supplementary Fig. 3) . 188 SARS-CoV-2 RNA load in TA was significantly higher (P<0.001) in presence than 189 absence of concomitant viral RNAemia (median, 9.5 log 10 copies/ml; range, 4.3 to 10.4 190 log 10 copies/ml vs. median, 6.2 log 10 copies/ml; range, 3.0-10.6 log 10 copies/ml). 191 SARS-CoV-2 N-antigenemia was detected in 43 samples from 30 patients (41.0%). 192

Median time to first N-antigenemia detection was 9 days after onset of symptoms 193 (range, 3-29 days). No patient had N-antigenemia beyond day 32 after symptoms onset. 194

The level of agreement between the qualitative results returned by plasma N-antigenemia assay was moderate (k=0.57; P=<0.0001). As shown in Fig. 4A , a trend 196 towards higher SARS-CoV-2 RNA loads was seen in plasma specimens testing positive 197 for N-antigenemia assay than in those yielding negative results (P=0.083). In turn, 198 SARS-CoV-2 RNA load in TA was significantly higher (P<0.001) in the presence of 199 concomitant N-antigenemia than in its absence (Fig. 4B) . 200

Plasma levels of ferritin and LDH, but not IL-6, CRP, or D-D, were significantly higher 203 when SARS-CoV-2 RNA was detected in paired TA or plasma specimens (Table 2 ), yet 204 SARS-CoV-2 RNA loads in TA and plasma correlated moderately with plasma levels 205 of ferritin and LDH ( Fig. 5A and 5B , respectively). The degree of correlation between 206 SARS-CoV-2 RNA load and serum levels biomarkers was similar when all respiratory 207 specimens (including NP) were considered for the analyses (not shown). 208

Plasma levels of all biomarkers except IL-6 were significantly higher in specimens 209 testing positive for SARS-CoV-2 N antigen than in those returning negative results 210 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted April 16, 2021. ; https://doi.org/10.1101/2021.04.16.21255601 doi: medRxiv preprint (Table 2) . Lymphocyte counts were significantly lower in the presence of SARS-CoV-2 211 RNA in TA and plasma or N antigen in plasma (Table 2) . Nevertheless, the level of 212 correlation (inverse) between SARS-CoV-2 RNA load in TA and plasma and 213 lymphocyte counts was modest (Fig. 6) . 214

Dynamics of SARS-CoV-2 RNA load (initial, peak and trajectory) in TA following ICU 216 admission were comparable across patients who either died or survived ( (Table 3) in multivariate models adjusted for 221 sex, age, comorbidities, APACHE II score and signs of organ failure. Occurrence of 222 SARS-CoV-2 N-antigenemia was not associated with increased mortality (P=0.59). 223

Here, we conducted a comprehensive comparative analysis of the kinetics of SARS-225

CoV-2 RNA load in the lower respiratory tract and blood compartment in a cohort of 226 adult COVID-19 patients admitted to ICU, of whom almost 90% underwent invasive 227 ventilation. The potential relationship between SARS-CoV-2 load in these 228 compartments and systemic inflammation status, absolute lymphocyte counts and 229 mortality was also investigated. In our view, the data presented herein could have 230 relevant pathogenetic implications, and the following findings are underlined. 231

First, from a kinetics perspective, SARS-CoV-2 load in TA showed a descending 232 trajectory from around two weeks after symptoms onset and was cleared in all survivors 233 at seven weeks. Interestingly, neither remdesivir nor tocilizumab appeared to have a 234 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted April 16, 2021. ; https://doi.org/10.1101/2021.04.16.21255601 doi: medRxiv preprint major impact on these kinetics. This is in line with previous studies showing that neither 235 drug had a tangible effect on SARS-CoV-2 RNA load in the upper airways, even when 236 administered early after symptoms onset [33, 34] . 237 SARS-CoV-2 RNAemia and N-antigenemia followed comparable time courses to viral 238 load in TA, but they cleared more rapidly. Detection of both viral RNAemia and N-239 antigenemia was more likely in patients exhibiting higher SARS-CoV-2 loads in TA. 240

Moreover, SARS-CoV-2 RNA load was substantially higher in TA than in paired 241 plasma, and a moderate correlation was found between SARS-CoV-2 RNA load in TA 242 and in paired plasma specimens. Collectively, these data suggested that LRT may be a 243 substantial source of SARS-CoV-2 RNA or N protein circulating in the peripheral blood 244 compartment. Given that detection of SARS-CoV-2 RNA in blood has not been 245 associated with infectious virus [19], we speculate that free RNA and soluble N protein, 246

probably leaking from the LRT (and perhaps from other tissue sources), are the main 247 biological forms of SARS-CoV-2 present in plasma. 248

Second, SARS-CoV-2 RNAemia could be documented in one or more specimens from 249 35.6% of patients. This figure is substantially lower than was reported for ICU patients 250 in other studies (77% in [14] and 88% in [18] ). In these studies [14,18], however, a 251 droplet-based digital PCR was used, which seemingly outperformed conventional RT-252 PCR assays such as the one used herein in terms of sensitivity. The above discrepancy 253 could also be related to different timing of sample collection across studies, potentially 254 important given the relatively rapid clearance of viral RNAemia documented in the 255 current study. 256

Third, SARS-CoV-2 N-antigenemia was detected in 41.0% of patients overall by means 257 of LFIC, with an analytical sensitivity of around 50 pg/ml: those exhibiting higher 258 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted April 16, 2021. ; https://doi.org/10.1101/2021.04.16.21255601 doi: medRxiv preprint plasma viral RNA loads were more likely to test positive, as previously reported [28] . 259

This concurs with the figure (49%) reported in a previous study [29] also using LFIC, 260 but is much lower than the proportion found by Hingrat et al. [28] in a small subcohort 261 of ICU patients (n=17), of whom most tested positive within the first two weeks after 262 symptoms onset. Notably, an ultrasensitive immunoassay (limit of detection of 2.8 263 pg/ml) was employed in that study [28] . We did not measure serum antibodies against 264 SARS-CoV-2, which may impact on the rate of N-antigenemia detection [29] , and 265 precludes certainty concerning the comparability of our data with those reported in the 266 other studies [28, 29] . Interestingly, in line with a previous report [28] , N-antigenemia 267 had a higher detection rate than viral RNAemia, which could be explained by the fact 268 that N protein is likely less prone to degradation than RNA in cryopreserved-thawed 269 specimens. We found a trend towards an association between qualitative detection of SARS-CoV-2 294 RNA in plasma and mortality in multivariate logistic regression models, and failed to 295 demonstrate higher initial or peak viral loads in deceased patients. We also found no 296 evidence of an association between detection of N-antigenemia and mortality rate. 297

Nevertheless, these data must be interpreted with caution due to the limited number of 298 death events in our series. 299

The main limitations of the current study are the relatively small sample size, the non-300 negligible number of missing specimens, specially TA, compared with the planned 301 sample collection schedule, and analytical methods which may have underestimated the 302 viral RNAemia and N-antigenemia detection rate. Analysis of sequential specimens 303 from patients could be considered a strength of the research. 304

The current study contributes to filling a knowledge gap on the comparative dynamics 305 of SARS-CoV-2 in LRT and in the systemic compartment in ICU patients, and provides 306 further insight into the pathogenesis of SARS-CoV-2 infection in this patient subset. In 307 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. 

This work received no public or private funds. 326

The authors declare no conflicts of interest. 328

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted April 16, 2021. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted April 16, 2021. ; . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted April 16, 2021. ; CRP, C-reactive protein; D-D, Dimer-D; IL-6, interleukin-6; LDH, lactose dehydrogenase.

.

It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted April 16, 2021. is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted April 16, 2021. ; https://doi.org/10.1101/2021.04.16.21255601 doi: medRxiv preprint SARS-CoV-2 RNA peak load in plasma (>5.6 vs. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted April 16, 2021. ; https://doi.org/10.1101/2021.04.16.21255601 doi: medRxiv preprint

,437) Ferritin in ng/ml

LDH in UI/l. Pos 105